You can buy or sell Agenus and other stocks, options, ETFs, and crypto commission-free!
Agenus Inc. Common Stock, also called Agenus, is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Read More Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 10
Agenus Q1 Earnings Beat Estimates, Revenues Miss
Agenus Inc. AGEN reported first-quarter 2019 earnings of 12 cents per share against the Zacks Consensus Estimate of a loss of 30 cents and the year-ago quarter’s loss of 42 cents. The company generated revenues of $8.6 million, which includes non-cash royalties, compared with no revenues in the year-ago quarter. Revenues marginally missed the Zacks Consensus Estimate of $9 million. Shares of the company have rallied 21% year to date compared with the industry’s growth of 3.3%. Quarterly Highlights Resea...
Yahoo FinanceMay 9
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
Expected Aug 8, Pre-Market